Welcure Drugs & Pharmaceuticals Ltd (524661)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Welcure Drugs' revenue was ₹0.0 Cr (-100.0% year on year), and net profit ₹-50.0 Cr (against a profit a year earlier).
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹0.0 | -100.0% | — |
| Operating profit | ₹-50.0 | to loss | — |
| Net profit | ₹-50.0 | to loss | to loss |
| EPS (₹) | adj. -0.36 | to loss | to loss |
EPS restated for the 1:10 bonus of Oct 2025: Q4 FY26 ₹-0.40 to ₹-0.36; Q3 FY26 ₹0.01 to ₹0.01.
📢 Recent Corporate Announcements
Welcure Drugs & Pharmaceuticals Ltd has announced the closure of its Corporate Office in Ahmedabad, Gujarat, effective July 14, 2026. The Board of Directors approved this move as an administrative decision aimed at operational efficiency and resource optimization. All statutory records and books of account will be transferred to the company's Registered Office in New Delhi. The company maintains that business operations will continue without interruption.
- Corporate office in Ahmedabad discontinued effective July 14, 2026
- Board meeting conducted for 40 minutes from 03:00 P.M. to 03:40 P.M.
- Statutory records to be consolidated at the Registered Office in New Delhi
- Decision taken for operational efficiency and resource optimization
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
